ClinicalTrials.gg
Active, not recruitingNCT04603495MANIFEST-2Updated Jul 17, 2026Results posted

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3 interventional study of Pelabresib and Ruxolitinib in Myelofibrosis, Primary Myelofibrosis and Post-polycythemia Vera Myelofibrosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 156 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Primary Myelofibrosis by Novartis — 1 open to participants now, 4 under way, 2 of them phase 3. Primary Myelofibrosis · Novartis.

Enrollment
4th of 21
430 · median 51
Started
2021
the only one that year
Phase 3
7 of 24
1 open now
Registered
19th of 24
by date

Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 3, and was the 19th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

1 of the 24 studies in Primary Myelofibrosis by Novartis is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Primary Myelofibrosis by Novartis, or all of them as a file.
02

Study summary

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

03

Conditions studied

  • Myelofibrosis
  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Browse trials for

Keywords

  • Pelabresib
  • Ruxolitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • Confirmed diagnosis of myelofibrosis (primary, post-polycythemia vera, or post essential thrombocythemia)
  • Adequate hematologic, renal, and hepatic function
  • Have at least 2 symptoms with an average score ≥ 3 or an average total score of ≥ 10 over the 7-day period prior to randomization using the MFSAF v4.0
  • Prognostic risk-factor score of Intermediate-1 or higher per Dynamic International Prognostic Scoring System (DIPSS) scoring system
  • Spleen volume of ≥ 450 cm\^3
  • (ECOG) performance status ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Splenectomy or splenic irradiation in the previous 6 months
  • Chronic or active conditions and/or concomitant medication use that would prohibit treatment
  • Had prior treatment with any JAKi or BET inhibitor for treatment of a myeloproliferative neoplasm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
430 participants (actual)

Study arms

  • Experimental
    Pelabresib + ruxolitinib

    Pelabresib monohydrate tablets + ruxolitinib phosphate tablets

    Drug: Pelabresib · Drug: Ruxolitinib

  • Active comparator
    Placebo + ruxolitinib

    Matching placebo tablets + ruxolitinib phosphate tablets

    Drug: Ruxolitinib · Drug: Placebo

Interventions

  • Double-blind treatment (pelabresib or matching placebo) will be administered daily for 14 consecutive days followed by a 7-day break, which is considered 1 cycle of treatment (1 cycle = 21 days). Pelabresib is a small molecule inhibitor of BET proteins with a novel mechanism of action and potential for disease-modifying effects in MF.

  • Ruxolitinib is a JAK inhibitor and a current, approved treatment option for MF.

  • DrugPlacebo

    Placebo tablets are designed to match pelabresib tablets. Each placebo tablet contains no active pharmaceutical ingredient and is visibly identical to experimental drug in size, shape, and packaging. Placebo dosing follows the same dosing conventions as pelabresib.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Splenic Response by Central Radiology Reads at Week 24

    Splenic response was characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 24.

    Time frame: Week 24

Secondary outcomes

  1. Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24

    The Total Symptom Score (TSS) at Week 24, compared to baseline, was measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represented the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflected a greater disease burden and therefore a worse outcome. The baseline TSS was calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week was determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores were available for a given week, the weekly TSS was considered missing.

    Time frame: Baseline, Week 24

  2. Key Secondary: Number of Participants With TSS50 Response at Week 24

    The probability of a TSS response at Week 24 was estimated by calculating the TSS response rate, defined as the percentage of patients who achieved a TSS50 response at Week 24 in each of the two treatment groups. The Total Symptom Score (TSS) response was defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.

    Time frame: Week 24

  3. Percent Change From Baseline in Total Symptom Score (TSS) at Week 24

    Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 measured the change in a patient's symptoms after 24 weeks of treatment, relative to baseline. A negative value indicates symptom improvement, and a reduction of ≥50% is typically considered a meaningful clinical response.

    Time frame: Baseline, Week 24

  4. Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24

    Improvement in bone marrow fibrosis by at least 1 grade, as assessed by central read compared to baseline, was analyzed by treatment group and overall. The improvement in bone marrow fibrosis grade was defined as a decrease by at least 1 grade in bone marrow fibrosis grade when compared to baseline, where a grade of MF-3 was the most severe, and MF-0 was the least severe.

    Time frame: Baseline, Week 24

  5. Number of Participants With Splenic Response by Central Radiology Reads at Week 48

    Splenic response is characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 48.

    Time frame: Week 48

  6. Number of Participants With TSS50 Response at Week 48

    The probability of a TSS response at Week 48 is estimated by calculating the TSS response rate, defined as the percentage of patients who achieve a TSS50 response at Week 48 in each of the two treatment groups. The Total Symptom Score (TSS) response is defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.

    Time frame: Week 48

  7. Absolute Change From Baseline in Total Symptom Score (TSS) at Week 48

    The Total Symptom Score (TSS) at Week 48, compared to baseline, is measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represents the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflects a greater disease burden and therefore a worse outcome. The baseline TSS is calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week is determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores are available for a given week, the weekly TSS is considered missing.

    Time frame: Baseline, Week 48

  8. Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment

    The rate of RBC transfusions was defined as the average number of RBC units transfused per patient month (4 weeks) during the first 24 weeks of treatment. The average number of RBC units per patient-month was calculated by dividing the total (ie, for all patients) number of RBC units in the whole exposure time by the sum of patient-months.

    Time frame: Week 24

  9. Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence

    Transfusion dependence (TD) was defined as having received ≥6 units of RBCs during the 12-week baseline period prior to dosing and Transfusion independence (TI) was defined as the absence of RBC transfusions during any continuous 12-week period of the double-blind treatment phase. The conversion from TD to TI was evaluated and defined as the proportion of patients who transitioned from transfusion dependence to transfusion independence. Patients who remained in the double-blind treatment period and had not received any RBC transfusions during the most recent 12 weeks were considered responders. Patients who discontinued from the double-blind treatment before Week 12 were classified as non-responders.

    Time frame: From 12-week baseline period prior to dosing to any 12-week period post baseline, up to 24 weeks

  10. Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24

    The Patient Global Impression of Change (PGIC) was a single-item measure of the patient's perceived change in MF symptoms since starting treatment. Patients responded to: "Since beginning this study treatment, your myelofibrosis symptoms were: (1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, (7) Very much worse."

    Time frame: Baseline, Week 24

  11. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS), defined as the time from randomization until documented progression, or until death from any cause for patients without documented progression

    Time frame: Through study completion, an average of 6 years

  12. Overall Survival (OS)

    OS, defined as the time from randomization until death from any cause

    Time frame: Through study completion, an average of 6 years

  13. Proportion of Patients With Transformation to Blast Phase (AML)

    Patients are categorized as having transformed to Acute Myelogenous Leukemia (AML) when the peripheral blood blast percentage increases to ≥20% and this elevation persists for at least two weeks, or when leukemic transformation is confirmed through disease status assessment.

    Time frame: Through study completion, an average of 6 years

  14. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    A treatment-emergent adverse event (TEAE) for the double-blind treatment period is defined as an AE that has a start date on or after the first dose of the pelabresib/placebo and before 30 days after the last dose of pelabresib/placebo or before the start of alternative (off-study) treatment for MF, whichever occurs first. If the AE has a start date before the date of first dose but increases in severity after first dose and before 30 days post last dose will be considered a TEAE as well. An AE that occurs after the administration of the first dose of open-label pelabresib treatment will be considered treatment-emergent for the crossover treatment period. However, a TEAE for the crossover treatment period that occurs within 30 days after the last dose of pelabresib/placebo will be considered treatment emergent for the double-blind treatment period as well.

    Time frame: Through study completion, an average of 6 years

  15. Pharmacokinetic (PK) Parameters for Pelabresib: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  16. Pharmacokinetic (PK) Parameters for Pelabresib: Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Tmax will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  17. Pharmacokinetic (PK) Parameters for Pelabresib: Maximum (Peak) Plasma Drug Concentration (Cmax)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Cmax will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  18. Pharmacokinetic (PK) Parameters for Pelabresib: Effective Half-Life (T1/2)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. T1/2 will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  19. Pharmacokinetic (PK) Parameters for Pelabresib: Apparent Volume of Distribution After Non-intravenous Administration (Vd/F)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. Vd/F will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  20. Pharmacokinetic (PK) Parameters for Pelabresib: Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)

    Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. CL/F will be listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  21. Ruxolitinib Plasma Concentrations in the Presence or Absence of Pelabresib

    Blood samples (approximately 4 mL each) will be collected at the time points specified in the Schedule of Assessments (SOA) to determine plasma concentrations of Ruxolitinib plasma concentrations in the presence or absence of Pelabresib

    Time frame: Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

  22. Duration of the Splenic Response

    Duration of splenic response, defined as the time from onset of splenic response until the time at which the patient has a \<35% decrease from baseline in spleen volume and a \>25% increase from nadir, as confirmed by the central review) or death, whichever comes first

    Time frame: Through study completion, an average of 6 years

  23. Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24

    The modified TSS (mTSS) was defined as TSS without the fatigue sub-domain and with a total scale of 60 points versus 70 points for TSS. Patients were classified as responders if the percentage of change from baseline in mTSS was ≤ -50% at Week 24.

    Time frame: Week 24

  24. Duration of the TSS50 Response

    Duration of TSS response, defined as the time from onset of TSS50 response until the time at which the patient has a \<50% reduction in TSS from baseline and an increase of ≥25% from nadir

    Time frame: Through study completion, an average of 6 years

07

Results

Posted Oct 28, 2024

Participant flow

A total of 135 centers enrolled patients in the study in Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Malaysia, Netherlands, Poland, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, and United States.

Participant flow — Overall Study
MilestonePelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Started214216
Modified intent-to-treat (mitt) analysis set212214
Safety analysis set212214
Per-protocol set (pp set)196194
Pharmacokinetic (pk) analysis set212211
Biomarker analysis set212214
Ongoing on double-blind treatment154160
Discontinued double-blind treatment5854
On pfs/os follow-up2230
Completed176190
Not completed3826
Withdrew: Adverse event21
Withdrew: Death1011
Withdrew: Lost to follow-up01
Withdrew: Physician decision33
Withdrew: Patient non-compliance/protocol violation(s)20
Withdrew: Withdrawal of consent for follow-up219
Withdrew: Patient became eligible for transplant01

Outcome measures

PrimaryNumber of Participants With Splenic Response by Central Radiology Reads at Week 24

Splenic response was characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Splenic Response by Central Radiology Reads at Week 24
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Number of Participants With Splenic Response by Central Radiology Reads at Week 2414176
Statistical analysis
  • Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm) · Cochran-Mantel-Haenszel · p = <0.001 · Difference in proportion: 30.4 · 95% CI 21.6 to 39.3The proportion difference = experimental group (Pela + RUX) - control group (placebo + RUX).
SecondaryKey Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24

The Total Symptom Score (TSS) at Week 24, compared to baseline, was measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represented the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflected a greater disease burden and therefore a worse outcome. The baseline TSS was calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week was determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores were available for a given week, the weekly TSS was considered missing.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24
score on a scalePelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24-15.99 ± 1.028-14.05 ± 0.986
Statistical analysis
  • Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm) · ANCOVA · p = 0.0545 · Ls mean difference: -1.94 · 95% CI -3.92 to 0.04
SecondaryKey Secondary: Number of Participants With TSS50 Response at Week 24

The probability of a TSS response at Week 24 was estimated by calculating the TSS response rate, defined as the percentage of patients who achieved a TSS50 response at Week 24 in each of the two treatment groups. The Total Symptom Score (TSS) response was defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Key Secondary: Number of Participants With TSS50 Response at Week 24
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Key Secondary: Number of Participants With TSS50 Response at Week 24112100
Statistical analysis
  • Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm) · Cochran-Mantel-Haenszel · p = 0.216 · Difference in proportions: 6.0 · 95% CI -3.4 to 15.5Proportion Difference = Experimental Group (Pela + RUX) - Control Group (placebo + RUX).
SecondaryPercent Change From Baseline in Total Symptom Score (TSS) at Week 24

Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 measured the change in a patient's symptoms after 24 weeks of treatment, relative to baseline. A negative value indicates symptom improvement, and a reduction of ≥50% is typically considered a meaningful clinical response.

Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change from baseline to Week 24
Percent Change From Baseline in Total Symptom Score (TSS) at Week 24
Percent change from baseline to Week 24Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Percent Change From Baseline in Total Symptom Score (TSS) at Week 24-50.3 (-56.6 to -44.0)-45.9 (-51.8 to -40.0)
SecondaryNumber of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24

Improvement in bone marrow fibrosis by at least 1 grade, as assessed by central read compared to baseline, was analyzed by treatment group and overall. The improvement in bone marrow fibrosis grade was defined as a decrease by at least 1 grade in bone marrow fibrosis grade when compared to baseline, where a grade of MF-3 was the most severe, and MF-0 was the least severe.

Time frame:
Baseline, Week 24
Reported as:
Count of participants · Participants
Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 243621
Statistical analysis
  • Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm) · Cochran-Mantel-Haenszel · p = 0.037 · Difference in proportions: 7.63 · 95% CI 0.52 to 14.73Proportion Difference = Experimental Group (Pela + RUX) - Control Group (placebo + RUX).
SecondaryNumber of Participants With Splenic Response by Central Radiology Reads at Week 48

Splenic response is characterized by a reduction of at least 35% in spleen volume from baseline (SVR35), as determined by magnetic resonance imaging (MRI) or computerized tomography (CT), and evaluated through a blinded central radiology review at Week 48.

Time frame:
Week 48

Results for this outcome have not been posted.

SecondaryNumber of Participants With TSS50 Response at Week 48

The probability of a TSS response at Week 48 is estimated by calculating the TSS response rate, defined as the percentage of patients who achieve a TSS50 response at Week 48 in each of the two treatment groups. The Total Symptom Score (TSS) response is defined as a ≥50% reduction from baseline in TSS, as measured by the Myelofibrosis Symptom Assessment Form v4.0.

Time frame:
Week 48

Results for this outcome have not been posted.

SecondaryAbsolute Change From Baseline in Total Symptom Score (TSS) at Week 48

The Total Symptom Score (TSS) at Week 48, compared to baseline, is measured using the Myelofibrosis Symptom Assessment Form v4.0. This score represents the sum of seven individual symptom items, each rated on a 0-10 scale, resulting in a possible total daily score ranging from 0 to 70. A higher TSS reflects a greater disease burden and therefore a worse outcome. The baseline TSS is calculated as the average of non-missing daily total symptom scores over the seven-day period preceding the day of randomization. The TSS for each treatment week is determined as the average of non-missing daily total symptom scores for that week. However, if fewer than four daily scores are available for a given week, the weekly TSS is considered missing.

Time frame:
Baseline, Week 48

Results for this outcome have not been posted.

SecondaryRate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment

The rate of RBC transfusions was defined as the average number of RBC units transfused per patient month (4 weeks) during the first 24 weeks of treatment. The average number of RBC units per patient-month was calculated by dividing the total (ie, for all patients) number of RBC units in the whole exposure time by the sum of patient-months.

Time frame:
Week 24
Reported as:
Number · RBC units transfused/patient-months
Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment
RBC units transfused/patient-monthsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment1.359 (0.982 to 1.736)1.014 (0.840 to 1.188)
SecondaryNumber of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence

Transfusion dependence (TD) was defined as having received ≥6 units of RBCs during the 12-week baseline period prior to dosing and Transfusion independence (TI) was defined as the absence of RBC transfusions during any continuous 12-week period of the double-blind treatment phase. The conversion from TD to TI was evaluated and defined as the proportion of patients who transitioned from transfusion dependence to transfusion independence. Patients who remained in the double-blind treatment period and had not received any RBC transfusions during the most recent 12 weeks were considered responders. Patients who discontinued from the double-blind treatment before Week 12 were classified as non-responders.

Time frame:
From 12-week baseline period prior to dosing to any 12-week period post baseline, up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence00
SecondaryCategory Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24

The Patient Global Impression of Change (PGIC) was a single-item measure of the patient's perceived change in MF symptoms since starting treatment. Patients responded to: "Since beginning this study treatment, your myelofibrosis symptoms were: (1) Very much improved, (2) Much improved, (3) Minimally improved, (4) No change, (5) Minimally worse, (6) Much worse, (7) Very much worse."

Time frame:
Baseline, Week 24
Reported as:
Count of participants · Participants
Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Very much improved2426
Much improved6362
Minimally improved6379
No change1413
Minimally worse714
Much worse50
Very much worse10
SecondaryProgression-Free Survival (PFS)

Progression-Free Survival (PFS), defined as the time from randomization until documented progression, or until death from any cause for patients without documented progression

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS, defined as the time from randomization until death from any cause

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

SecondaryProportion of Patients With Transformation to Blast Phase (AML)

Patients are categorized as having transformed to Acute Myelogenous Leukemia (AML) when the peripheral blood blast percentage increases to ≥20% and this elevation persists for at least two weeks, or when leukemic transformation is confirmed through disease status assessment.

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

A treatment-emergent adverse event (TEAE) for the double-blind treatment period is defined as an AE that has a start date on or after the first dose of the pelabresib/placebo and before 30 days after the last dose of pelabresib/placebo or before the start of alternative (off-study) treatment for MF, whichever occurs first. If the AE has a start date before the date of first dose but increases in severity after first dose and before 30 days post last dose will be considered a TEAE as well. An AE that occurs after the administration of the first dose of open-label pelabresib treatment will be considered treatment-emergent for the crossover treatment period. However, a TEAE for the crossover treatment period that occurs within 30 days after the last dose of pelabresib/placebo will be considered treatment emergent for the double-blind treatment period as well.

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC0-t)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Time to Reach Maximum (Peak) Plasma Concentration Following Drug Administration (Tmax)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Tmax will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Maximum (Peak) Plasma Drug Concentration (Cmax)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. AUC0-t will be listed and summarized using descriptive statistics. Cmax will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Effective Half-Life (T1/2)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. T1/2 will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Apparent Volume of Distribution After Non-intravenous Administration (Vd/F)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. Vd/F will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryPharmacokinetic (PK) Parameters for Pelabresib: Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F)

Pharmacokinetic (PK) parameters will be calculated based on Pelabresib plasma concentrations and actual sampling time points. CL/F will be listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryRuxolitinib Plasma Concentrations in the Presence or Absence of Pelabresib

Blood samples (approximately 4 mL each) will be collected at the time points specified in the Schedule of Assessments (SOA) to determine plasma concentrations of Ruxolitinib plasma concentrations in the presence or absence of Pelabresib

Time frame:
Cycle 1 Day 1, Cycle 1 Day 14 and Cycle 9 Day 1: Predose, 30 minutes to 1 hour post-dose, 3 to 4.5 hours post-dose. Cycle 3 and Cycle 7 Day 1: Predose, 5 minutes post ECG assessment. 1 Cycle = 21 days

Results for this outcome have not been posted.

SecondaryDuration of the Splenic Response

Duration of splenic response, defined as the time from onset of splenic response until the time at which the patient has a \<35% decrease from baseline in spleen volume and a \>25% increase from nadir, as confirmed by the central review) or death, whichever comes first

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Modified Total Symptom Score (mTSS) Response at Week 24

The modified TSS (mTSS) was defined as TSS without the fatigue sub-domain and with a total scale of 60 points versus 70 points for TSS. Patients were classified as responders if the percentage of change from baseline in mTSS was ≤ -50% at Week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24
ParticipantsPelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)
Number of Participants With Modified Total Symptom Score (mTSS) Response at Week 24120104
Statistical analysis
  • Pelabresib + Ruxolitinib (Experimental Arm) vs Placebo + Ruxolitinib (Control Arm) · Cochran-Mantel-Haenszel · p = 0.107 · Difference in proportions: 7.8 · 95% CI -1.7 to 17.2The proportion difference = experimental group (Pela + RUX) - control group (placebo + RUX). Wald 95% CIs were applied.
SecondaryDuration of the TSS50 Response

Duration of TSS response, defined as the time from onset of TSS50 response until the time at which the patient has a \<50% reduction in TSS from baseline and an increase of ≥25% from nadir

Time frame:
Through study completion, an average of 6 years

Results for this outcome have not been posted.

Adverse events

Collected over Adverse Events (AEs) on-treatment period are collected from the first dose of pelabresib/placebo until 30 days after the last dose of pelabresib/placebo or the initiation of alternative (off-study) treatment for myelofibrosis (MF), whichever occurred first, up to the cut-off date for the interim analysis (31-Aug-2023), an average of 47 weeks. Deaths were collected from start of study up to the cut-off date for the interim analysis (31-Aug-2023), up to approximately of 28 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pelabresib + Ruxolitinib (On-Treatment)5/214 (2.3%)63/212 (29.7%)199/212 (93.9%)
Placebo + Ruxolitinib (On-Treatment)6/216 (2.8%)63/214 (29.4%)200/214 (93.5%)
Pelabresib + Ruxolitinib (Post-Treatment)7/209 (3.3%)——
Placebo + Ruxolitinib (Post-Treatment)5/210 (2.4%)——
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventPelabresib + Ruxolitinib (On-Treatment)Placebo + Ruxolitinib (On-Treatment)Pelabresib + Ruxolitinib (Post-Treatment)Placebo + Ruxolitinib (Post-Treatment)
PneumoniaInfections and infestations7/2126/214——
AnaemiaBlood and lymphatic system disorders5/2125/214——
Herpes zosterInfections and infestations4/2120/214——
SepsisInfections and infestations3/2122/214——
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/2122/214——
Cardiac failureCardiac disorders0/2123/214——
COVID-19Infections and infestations0/2123/214——
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2123/214——
ArrhythmiaCardiac disorders2/2120/214——
Cardiac arrestCardiac disorders2/2120/214——
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPelabresib + Ruxolitinib (On-Treatment)Placebo + Ruxolitinib (On-Treatment)Pelabresib + Ruxolitinib (Post-Treatment)Placebo + Ruxolitinib (Post-Treatment)
AnaemiaBlood and lymphatic system disorders90/212116/214——
ThrombocytopeniaBlood and lymphatic system disorders68/21250/214——
ConstipationGastrointestinal disorders39/21252/214——
DiarrhoeaGastrointestinal disorders49/21239/214——
Platelet count decreasedInvestigations44/21234/214——
DysgeusiaNervous system disorders39/2128/214——
FatigueGeneral disorders25/21234/214——
NauseaGastrointestinal disorders30/21232/214——
COVID-19Infections and infestations24/21232/214——
AstheniaGeneral disorders25/21230/214——

Baseline characteristics

Intent-to-Treat Population. All randomized patients. This is the primary population for all efficacy endpoints. All analyses using this population will be based on the treatment assigned by the Interactive Response Technology (IRT) system.

Age, Categorical
Age, Categorical(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
<=18 years000
Between 18 and 65 years9492186
>=65 years120124244
Age, Continuous
Age, Continuous(years)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
Mean64.5 ± 11.8464.8 ± 11.0864.7 ± 11.45
Sex: Female, Male
Sex: Female, Male(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
Female8594179
Male129122251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
Hispanic or Latino369
Not Hispanic or Latino194199393
Unknown or Not Reported171128
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
American Indian or Alaska Native101
Asian354277
Native Hawaiian or Other Pacific Islander000
Black or African American202
White160163323
More than one race000
Unknown or Not Reported161127
Dynamic International Prognostic Scoring System (DIPSS) risk category
Dynamic International Prognostic Scoring System (DIPSS) risk category(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
Intermediate-1128127255
Intermediate-27574149
High111526
Platelet count
Platelet count(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
>200 × 10^9 cells/L154157311
100-200 × 10^9 cells/L5957116
<100 × 10^9 cells/L123
Hemoglobin
Hemoglobin(Participants)Pelabresib + Ruxolitinib (Experimental Arm)Placebo + Ruxolitinib (Control Arm)Total
>10 g/dL144140284
≤10 g/dL7076146

3 further baseline measures are reported on the registry.

08

Study locations

156 sites

Showing the first 100 of 156 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larran A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. PubMed 35950489 ↗
  • Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, Patriarca A, Alvarez-Larran A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025 May;31(5):1531-1538. doi: 10.1038/s41591-025-03572-3. Epub 2025 Mar 10. PubMed 40065169 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2023, 28 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2020
First posted
Oct 26, 2020
StartActual
Apr 9, 2021
Primary completionActual
Aug 23, 2023
CompletionEst.
Jun 30, 2027
Results first posted
Oct 28, 2024
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04603495
Responsible party
Sponsor
First posted
Oct 26, 2020
Start date
Apr 9, 2021
Primary completion
Aug 23, 2023
Completion
Jun 30, 2027 (estimated)
Results posted
Oct 28, 2024
Last update
Jul 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CPI-0610

Start the discussion